Nang Kuang Pharmaceutical Co., Ltd.
8
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
37.5%
3 terminated/withdrawn out of 8 trials
57.1%
-29.4% vs industry average
50%
4 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
Role: lead
A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers
Role: lead
A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340)
Role: lead
Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain
Role: lead
A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus
Role: lead
Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer
Role: lead
A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain
Role: lead
Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease
Role: lead
All 8 trials loaded